841 related articles for article (PubMed ID: 15548764)
1. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
2. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
[TBL] [Abstract][Full Text] [Related]
3. The hERG channel activator, RPR260243, enhances protective
Shi YP; Pang Z; Venkateshappa R; Gunawan M; Kemp J; Truong E; Chang C; Lin E; Shafaattalab S; Faizi S; Rayani K; Tibbits GF; Claydon VE; Claydon TW
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H251-H261. PubMed ID: 32559136
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
Perry M; Sachse FB; Sanguinetti MC
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13827-32. PubMed ID: 17693551
[TBL] [Abstract][Full Text] [Related]
6. A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.
Perry M; Sanguinetti MC
Mol Pharmacol; 2008 Apr; 73(4):1044-51. PubMed ID: 18162604
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological characterization of the hERG R56Q LQTS variant and targeted rescue by the activator RPR260243.
Kemp JM; Whittaker DG; Venkateshappa R; Pang Z; Johal R; Sergeev V; Tibbits GF; Mirams GR; Claydon TW
J Gen Physiol; 2021 Oct; 153(10):. PubMed ID: 34398210
[TBL] [Abstract][Full Text] [Related]
8. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
9. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
10. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
Zhou Z; Gong Q; Ye B; Fan Z; Makielski JC; Robertson GA; January CT
Biophys J; 1998 Jan; 74(1):230-41. PubMed ID: 9449325
[TBL] [Abstract][Full Text] [Related]
11. C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.
Gardner A; Sanguinetti MC
Mol Pharmacol; 2015 Jul; 88(1):19-28. PubMed ID: 25888115
[TBL] [Abstract][Full Text] [Related]
12. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.
Kang J; Chen XL; Wang L; Rampe D
J Pharmacol Exp Ther; 2001 Oct; 299(1):290-6. PubMed ID: 11561091
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological characterization of a small molecule activator on human ether-a-go-go-related gene (hERG) potassium channel.
Dong X; Liu Y; Niu H; Wang G; Dong L; Zou A; Wang K
J Pharmacol Sci; 2019 Jul; 140(3):284-290. PubMed ID: 31481348
[TBL] [Abstract][Full Text] [Related]
14. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
16. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
17. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
Trepakova ES; Dech SJ; Salata JJ
J Cardiovasc Pharmacol; 2006 Feb; 47(2):211-20. PubMed ID: 16495758
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
Gerlach AC; Stoehr SJ; Castle NA
Mol Pharmacol; 2010 Jan; 77(1):58-68. PubMed ID: 19805508
[TBL] [Abstract][Full Text] [Related]
19. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
20. Activators of cation channels: potential in treatment of channelopathies.
Seebohm G
Mol Pharmacol; 2005 Mar; 67(3):585-8. PubMed ID: 15608141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
